Ovarian Neoplasms Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for ovarian neoplasms in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Hospital of the University of Pennsylvania ( Site 0071), Philadelphia, Pennsylvania
    Locations
    163 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT07318558 on ClinicalTrials.gov

  2. A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

    This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed d…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Pennsylvania Hospital, Philadelphia, Pennsylvania
    Locations
    267 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07213804 on ClinicalTrials.gov

  3. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    30 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07213791 on ClinicalTrials.gov

  4. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia, Pennsylvania
    Locations
    19 in total
    Run by
    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.